AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Original) A compound represented by formula (I):



(I)

wherein ring A represents a 3- to 15-membered nitrogen-containing mono-, bi- or tri-cyclic hetero ring which may have a substituent(s);

ring B may have, at the 6-position, an aliphatic hydrocarbon group which may have a substituent(s), a cyclic group which may have a substituent(s), a hydroxyl group which may be protected, a carboxyl group which may be protected, or a carbamoyl group which may be substituted, or



wherein Q^1 and Q^2 each independently represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s), a cyclic group which may have a substituent(s), a hydroxyl group which may be protected, a carboxyl group which may be protected, or a carbamoyl group which may be substituted;

R^1 represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s), or a cyclic group which may has a substituent(s);

R^2 and R^3 each independently represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s), a cyclic group which may have a substituent(s), a hydroxyl group which may be protected, a carboxyl group which may be protected, or a carbamoyl group which may be substituted, and

wherein, when ring A is  , ring A has a substituent(s) other than R^1, or

a salt thereof, a solvate thereof, or a prodrug thereof.

2. (Original) The compound according to claim 1, wherein ring A is a 4- to 8-membered nitrogen-containing mono-cyclic hetero ring or a 9- to 15-membered nitrogen-containing bi- or tri-cyclic hetero ring which may have a substituent(s), or a salt thereof, a solvate thereof, or a prodrug thereof.

3. (Original) The compound according to claim 1, wherein ring A is





wherein, when ring A is  , ring A has a substituent(s) other than R^1, or a salt thereof, a solvate thereof, or a prodrug thereof.

4. (Original) The compound according to claim 1, wherein R^1 is an aliphatic hydrocarbon group which may have a substituent(s), a salt thereof, a solvate thereof, or a prodrug thereof.

5. (Original) The compound according to claim 1, wherein ring B is an aliphatic hydrocarbon group which may have a substituent(s), a salt thereof, a solvate thereof, or a prodrug thereof.

6. (Original) The compound according to claim 1, wherein R^3 is hydrogen, a salt thereof, a solvate thereof, or a prodrug thereof.

7. (Currently Amended) A pharmaceutical composition comprising~~, as an active ingredient,~~ the compound according to claim 1, a salt thereof, a solvate thereof, or a prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

8. (Original) The pharmaceutical composition according to claim 7, which is a chemokine receptor antagonist.

9. (Original) The pharmaceutical composition according to claim 8, wherein the chemokine receptor is CCR5.

10. (Original) The pharmaceutical composition according to claim 7, which is a preventive and/or therapeutic agent for CCR5-related diseases.

11. (Original) The pharmaceutical composition according to claim 7, which is a preventive and/or therapeutic agent for human immunodeficiency virus infection.

12. (Original) The pharmaceutical composition according to claim 7, which is a preventive and/or therapeutic agent for acquired immunodeficiency syndrome.

13. (Original) The pharmaceutical composition according to claim 7, which is a preventive and/or therapeutic agent for transplanted organ rejection reactions.

14. (Original) A medicament which comprises a combination of the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof, or a prodrug thereof with one or at least two of agents selected from reverse transcriptase inhibitors, protease inhibitors, CCR2 antagonists, CCR3 antagonists, CCR4 antagonists, CXCR4 antagonists, fusion inhibitors, HIV integrase inhibitors, antibodies against a surface antigen of HIV-1 and vaccines against HIV-1.

15. (Original) A method for preventing and/or treating CCR5-related diseases in a mammal, which comprises administering to a mammal an effective amount of the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof, or a prodrug thereof.

16. (Original) A method for preventing and/or treating immunodeficiency virus infection in a mammal, which comprises administering to a mammal an effective amount of the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof, or a prodrug thereof.

Claims 17-18. (Cancelled)